Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

Article Tools

• Email

  Thank you for your interest in spreading the word about Science Translational Medicine.

  NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

  Your Email

  Your Name

  Send To

  Enter multiple addresses on separate lines or separate them with commas.

  You are going to email the following Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

  Message Subject (Your Name) has forwarded a page to you from Science Translational Medicine

  Message Body (Your Name) thought you would like to see this page from the Science Translational Medicine web site.

  Your Personal Message

  Send Message
• Download Powerpoint
• Print
• Alerts

  Please log in to add an alert for this article.

  Log In with your AAAS ID

  Sign In to Email Alerts with your Email Address

  Email

  Log in
• Citation tools

  Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

  By Yan Lan, Dong Zhang, Chunxiao Xu, Kenneth W. Hance, Bo Marelli, Jin Qi, Huakui Yu, Guozhong Qin, Aroop Sircar, Vivian M. Hernández, Molly H. Jenkins, Rachel E. Fontana, Amit Deshpande, George Locke, Helen Sabzevari, Laszlo Radvanyi, Kin-Ming Lo

  Science Translational Medicine17 Jan 2018

  Blockade of PD-L1 and TGF-β pathways with M7824 activates effective innate and adaptive antitumor immune responses.

  • Supplementary Materials

  Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
• Share

  Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

  By Yan Lan, Dong Zhang, Chunxiao Xu, Kenneth W. Hance, Bo Marelli, Jin Qi, Huakui Yu, Guozhong Qin, Aroop Sircar, Vivian M. Hernández, Molly H. Jenkins, Rachel E. Fontana, Amit Deshpande, George Locke, Helen Sabzevari, Laszlo Radvanyi, Kin-Ming Lo

  Science Translational Medicine17 Jan 2018

  Blockade of PD-L1 and TGF-β pathways with M7824 activates effective innate and adaptive antitumor immune responses.

  • Supplementary Materials

  Share This Article: Copy